(January 31, 2024, 12:29 PM EST) -- WASHINGTON, D.C. — Koninklijke Philips NV said in a U.S. Securities and Exchange Commission filing that it has agreed to terms of a consent decree with the U.S. Food and Drug Administration related to the recall of approximately 10.8 million continuous positive air pressure (CPAP) sleep apnea devices and respirators and that as part of the decree, it will pause its sale of sleep therapy devices or other respiratory care devices in the United States....